Sutro Biopharma Inc

NASDAQ:STRO   3:59:55 PM EDT
26.93
-0.10 (-0.37%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.22B
Current PE96.94
Forward PE 336.63
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.27 Million
Adjusted EPS-$0.57
See more estimates
10-Day MA$25.58
50-Day MA$20.84
200-Day MA$12.69
See more pivots

SUTRO BIOPHARMA INC Stock, NASDAQ:STRO

310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO, CA 94080
Phone: 650-392-8412
Number of Employees: 147

Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.